Maker of weight-loss drugs to ask Trump to pause price negotiations: Report
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price negotiations that were put in place by the Biden administration's Inflation Reduction Act (IRA). "They need to fix [the IRA]," Eli Lilly CEO Dave Ricks told Bloomberg at the JPMorgan Healthcare Conference in San Francisco.
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
GLP-1 medications like Ozempic, Wegovy, and Mounjaro are linked to reduced risks of dementia, heart failure, and severe ...
The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on ...
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.
A new study found that GLP-1 medications like Ozempic can lower your risk for 42 conditions, including dementia. Here's what ...
A registered dietitian shares the best drinks to support healthy weight management while taking weight loss medications.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback